Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc.
April 06 2021 - 8:00AM
Business Wire
Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX)
("Brooklyn" or “the Company”), a biopharmaceutical company focused
on exploring the role that cytokine-based therapy can have in
treating patients with cancer, today announced the appointment of
Howard J. Federoff, M.D., Ph.D., as Chief Executive Officer and
President and a director as of 16 April 2021. Dr. Federoff succeeds
Ronald Guido who was serving as Interim CEO and will remain on
Brooklyn’s management team as Chief Development Officer.
“Dr. Federoff brings an unwavering focus on the patient as well
as an outstanding record of clinical, academic and corporate
achievement to Brooklyn ImmunoTherapeutics,” said Charles
Cherington, Director of Brooklyn. “Dr. Federoff’s unparalleled
record of professional accomplishments and experience will be a
tremendous asset to Brooklyn ImmunoTherapeutics as we advance the
clinical development of IRX-2 as well as explore potential new
opportunities. We look forward to working with Dr. Federoff to
bring new treatment options to patients living with cancer and
other serious diseases.”
“Brooklyn’s IRX-2 product offers a significant opportunity to
improve patient outcomes both as a monotherapy and in combination
with other anti-cancer drugs including immune-oncology therapies,”
said Dr. Federoff. “My top priorities will be the clinical
advancement of IRX-2 in solid tumor indications as well as seeking
opportunities to in-license new therapeutic agents that can extend
and enhance the lives of patients fighting cancer and other serious
diseases. This is an exciting time in oncology drug development and
I believe that Brooklyn ImmunoTherapeutics will be a leader in
advancing patient care.”
Dr. Federoff is a distinguished professor of neurology at the
University of California, Irvine. He is the former CEO of UCI
Health, vice chancellor for health affairs and dean of the UCI
School of Medicine. Prior to joining UCI Health, Federoff was
executive vice president of Health Sciences and executive dean at
Georgetown University. Dr. Federoff has published more than 275
peer-reviewed and invited articles, and serves on editorial boards
of five journals. He co-founded MedGenesis Therapeutix and Brain
Neurotherapy Bio, both advancing therapeutics for neurologic
diseases. He became CEO of the regenerative medicine company, Aspen
Neuroscience, Inc, in San Diego. Aspen is developing an autologous
iPSC drug product for Parkinson’s disease. Dr. Federoff chaired the
NIH Recombinant DNA Advisory Committee, the NHLBI Gene Therapy
Resource and the Board of the Association of the Academic Health
Centers. He has served as an advisor/director for several
companies. He is an elected Fellow of the American Association for
the Advancement of Science and the National Academy of Inventors.
He received his MD, MS and PhD in biochemistry from the Albert
Einstein College of Medicine in New York. He completed his
residency and clinical and research fellowships at Massachusetts
General Hospital and Harvard Medical School.
About Brooklyn ImmunoTherapeutics
Brooklyn is focused on exploring the role that cytokine-based
therapy can have in treating patients with cancer, both as a single
agent and in combination with other anti-cancer therapies. The
company is also exploring opportunities to advance therapies using
leading edge gene editing/cell therapy technology through its
option agreement with Factor Bioscience/Novellus.
Brooklyn’s most advanced program is studying the safety and
efficacy of IRX-2 in patients with head and neck cancer. In a Phase
2A clinical trial in head and neck cancer, IRX-2 demonstrated an
overall survival benefit. Additional studies are either underway or
planned in other solid tumor cancer indications.
For more information about Brooklyn and its clinical programs,
please visit www.BrooklynITx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210406005284/en/
Media:
MacDougall Nicholas Chang nchang@macbiocom.com 781-235-3060
Investor Relations:
CORE IR 516-222-2560 investors@brooklynitx.com
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Brooklyn ImmunoTherapeut... (AMEX:BTX)
Historical Stock Chart
From Jul 2023 to Jul 2024